As year-end wholesale acquisition cost (WAC) decreases loom, 340B covered entities find themselves navigating a complex landscape that significantly impacts their financial health. Unlike other pharmacies, covered entities contend with multiple purchasing accounts, intricate rebate mechanics, and contract-pharmacy restrictions, all converging on high-volume brand medications. The recent round of WAC reductions affects crucial drugs like Eliquis, Jardiance, and Humalog, transforming what would typically be a straightforward pricing event into a multifaceted challenge involving margins, cash flow, and contract management for both owned outpatient and contract pharmacies.
In this blog post, we will explore the unique margin pressures faced by covered entity–owned pharmacies, highlighting the implications of WAC cuts on acquisition costs and 340B rebates. Additionally, we will delve into the shared risks borne by contract pharmacies and how these changes can create tensions in revenue-sharing models. Finally, we will outline essential action steps for 340B leadership to proactively manage inventory and mitigate financial impacts, ensuring both owned pharmacies and contract networks can adapt effectively during these turbulent times.
Understanding margin challenges for covered entity–owned pharmacies amid WAC decreases
As the new year approaches, covered entity–owned pharmacies face significant margin challenges due to impending Average Wholesale Price (AWP) reductions. These reductions impact their purchasing dynamics, as pharmacies often utilize multiple accounts for a single National Drug Code (NDC) — such as 340B, Group Purchasing Organization (GPO), and WAC/non-contract accounts. When these prices drop, it creates a ripple effect on reimbursements from Pharmacy Benefit Managers (PBMs) and payers, who quickly adjust their payment rates to reflect the decreased WAC. The result? December inventory on GPO/WAC accounts becomes riskier, leading to negative or zero margins as pharmacies struggle to sell through their existing stock.
Moreover, the implications extend beyond immediate cash flow issues. While 340B-eligible claims may initially provide reasonable margins, non-340B scripts face heightened risk of financial loss. Medicaid carve-outs or ineligible locations exacerbate this risk, leaving pharmacies navigating a complex landscape where some product lines become less profitable. The convergence of WAC cuts and the rebate model further complicates this scenario, as rebates decrease alongside acquisition costs, limiting the financial recovery on drugs purchased prior to the price decrease. As a result, it's imperative for covered entity–owned pharmacies to reassess their purchasing strategies and inventory management practices to mitigate the impact of these WAC changes.
Navigating complexities for contract pharmacies with shared risks during WAC cuts
Contract pharmacies face significant hurdles during WAC decreases, mirroring the initial challenges of community pharmacies but compounded by the 340B framework's unique dynamics. When wholesale acquisition costs drop, contract pharmacies find themselves under financial strain, holding high-cost inventory while reimbursements quickly adjust to the new lower prices. This mismatch leads to an immediate risk to their cash flow and profitability. As these pharmacies typically own the inventory and bear the initial acquisition costs, they experience the pain of diminished margins directly, while the covered entities continue to expect their share of the 340B value generated from eligible claims.
In this environment, the relationship between contract pharmacies and covered entities becomes even more critical yet fraught with tension. Contract pharmacies may request renegotiation of fees or revenue splits to account for their losses from inventory purchased at higher WAC prices. These negotiation discussions become essential, particularly when existing contracts do not adequately address the risks associated with fluctuating WAC prices and their consequences on financial arrangements. As contract pharmacies seek clarity on the sharing of 340B rebates and MFP refunds, covered entities must respond proactively by updating agreements and establishing expectations that reflect this new reality. Emphasizing open communication and collaborative problem-solving will be crucial for maintaining these vital partnerships amid challenging market conditions.
Proactive action steps for 340B leadership to manage inventory and financial impact
To effectively navigate the complexities arising from upcoming WAC decreases, 340B leadership must adopt a proactive approach in inventory and financial management. Start by identifying at-risk NDCs across different purchasing accounts—namely 340B, GPO, and WAC. Conduct a thorough review of your inventory ahead of anticipated WAC cuts, prioritizing the dispensing of high-WAC items when clinically appropriate. This strategic dispensing will help reduce the financial strain of products purchased at the higher cost, allowing you to mitigate potential losses before price adjustments take effect. Additionally, create a detailed map highlighting overlaps between WAC-cut drugs, rebate-model drugs, and IRA Maximum Fair Price drugs (MFP) to stress-test the overall impact on your 340B savings.
Updating agreements with contract pharmacies is equally important. Share a targeted list of NDCs affected by WAC decreases and encourage your contract partners to adopt leaner stocking practices as year-end approaches. It is crucial to clarify inventory risk regarding WAC decreases in your agreements, as well as define the treatment of 340B rebates and MFP refunds. Establishing clear expectations for data submission and reporting will minimize misunderstandings when navigating these financial shifts. Finally, schedule regular joint reviews with your largest contract pharmacies to discuss the economic impacts and aligned strategies moving forward. This proactive, system-wide risk management plan will provide a roadmap for both your owned pharmacy and your contract-pharmacy network to thrive amidst the challenges posed by WAC decreases.